AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (4.3 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Human urine-derived stem cells rescue cutaneous manifestation and suppress inflammation and fibrosis in vitro and in a mouse model of recessive dystrophic epidermolysis bullosa

Xingli Zhou1, Jie Tan2,3,Yuting Song2,Pengcheng Liu2Xiwen Zhang1Xun Feng1Yue Xiao1Yiyi Wang1Guoqing Liu1Wenqian Zhang2Qingyi Zhang2Yanlin Jiang2Yuan Liu2Longmei Zhao2Huiqi Xie2,§ ( )Wei Li1,§ ( )
Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
Department of Spine Surgery, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518041, China

These authors have contributed equally to this work.

§These co-corresponding authors contributed equally to this work.

Show Author Information

Highlights

• This study demonstrates that human USCs have several positive key properties on RDEB both in vitro with tissue-engineered skin in a three-dimensional co-culture system and in vivo with COL7A1−/− (RDEB) mice.

• USCs could improve the expression of C7 at the dermis–epidermis junction of skin from RDEB mice.

• USCs exert a suppressive effect on inflammation and fibrosis progression of keratinocytes and fibroblasts of RDEB mice.

Abstract

Background

Recessive dystrophic epidermolysis bullosa (RDEB) is a life-threatening disease characterized by persistent wound inflammation, tissue fibrosis, and even tumorigenesis in later stages. Despite its significant impact on patient health worldwide, treatment of RDEB has limited options. There is a clear need for now interventions. The goal of this study was to explore the potential efficacy of urine-derived stem cells (USCs) in RDEB.

Methods

We isolated human USCs from healthy donors, and assessed their therapeutic effects on RDEB both in vitro with tissue-engineered skin in a three-dimensional co-culture system and in vivo with COL7A1−/− (RDEB) mice.

Results

USCs showed suppressive effects on expression of inflammation- and fibrosis-related genes involved in RDEB in vitro and in vivo. USCs could also extend the median life span (from 3 to 5 days), improve the expression of C7, and migrate to various organs of RDEB mice after intrahepatic administration.

Conclusions

In summary, these results suggest the potential effects of USCs on improving the expression of C7 and would repair of RDEB, which supports the future use of USCs for the treatment of RDEB patients.

Graphical Abstract

References

【1】
【1】
 
 
Burns & Trauma
Article number: tkaf058

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhou X, Tan J, Song Y, et al. Human urine-derived stem cells rescue cutaneous manifestation and suppress inflammation and fibrosis in vitro and in a mouse model of recessive dystrophic epidermolysis bullosa. Burns & Trauma, 2025, 13(12): tkaf058. https://doi.org/10.1093/burnst/tkaf058

2

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

Received: 18 November 2024
Revised: 12 August 2025
Accepted: 20 August 2025
Published: 21 August 2025
© The Author(s) 2025. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.